Nanomedicine in non-small cell lung cancer: From conventional treatments to immunotherapy

Coral García-Fernández, Cristina Fornaguera, Salvador Borrós

Producció científica: Article en revista indexadaArticle de revisió (sistemàtica)Avaluat per experts

26 Cites (Scopus)


Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs.

Idioma originalAnglès
Número d’article1609
Pàgines (de-a)1-26
Nombre de pàgines26
Estat de la publicacióPublicada - de juny 2020


Navegar pels temes de recerca de 'Nanomedicine in non-small cell lung cancer: From conventional treatments to immunotherapy'. Junts formen un fingerprint únic.

Com citar-ho